

GHD Reversal Trial: Baseline Data Collection Worksheet

Trial Number Participant DOB e.g. JAN-2017

Site name

Section 1 - Visit Details

Assessment Date e.g. 31-JAN-2017 - -

Section 2 - Ethnicity

Participant's self declared ethnicity *Please tick one*

<input type="radio"/> British European	<input type="radio"/> Irish European	<input type="radio"/> Central European
<input type="radio"/> East European	<input type="radio"/> North European	<input type="radio"/> South European
<input type="radio"/> West European	<input type="radio"/> North African	<input type="radio"/> Sub-Saharan African
<input type="radio"/> Middle Eastern	<input type="radio"/> Indian	<input type="radio"/> Pakistani
<input type="radio"/> Bangladeshi	<input type="radio"/> Chinese	<input type="radio"/> Other East Asian
<input type="radio"/> South East Asian	<input type="radio"/> Caribbean	<input type="radio"/> European and East Asian
<input type="radio"/> European and South Asian	<input type="radio"/> European and Sub-Saharan African	<input type="radio"/> European and Caribbean
<input type="radio"/> Any Other Mixed Background*	<input type="radio"/> Other*	<input type="radio"/> Declined to give information

*If 'Any other mixed background' or 'Other', please specify

Section 3 - Clinical Details

Participant's height (mean) *See Protocol V4.0, Section 10.5 for clarification of measurement procedure.* . cm

Participant's weight . kg

Target height *Calculated as: (Mother's height + Father's height) / 2 ± 6.5cm. The 6.5cm should be added for males and subtracted for females.*
 . cm

Tanner stage (P) *Please tick one* Stage 2 Stage 3 Stage 4 Stage 5

Section 4 - Details of Diagnosis

GH Stimulation Tests at Diagnosis

	Date sample taken	Peak GH	Test used	Was the test sex steroid primed?
1st stimulation test	<input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	<input type="text"/> <input type="text"/> . <input type="text"/> µg/L	<input type="radio"/> Insulin tolerance test <input type="radio"/> Arginine <input type="radio"/> Glucagon <input type="radio"/> Other	<input type="radio"/> Yes <input type="radio"/> No
2nd stimulation test	<input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	<input type="text"/> <input type="text"/> . <input type="text"/> µg/L	<input type="radio"/> Insulin tolerance test <input type="radio"/> Arginine <input type="radio"/> Glucagon <input type="radio"/> Other	<input type="radio"/> Yes <input type="radio"/> No

If 'Other' test used for 1st stimulation test, please specify

If 'Other' test used for 2nd GH stimulation test, please specify

Diagnostic peak GH cut off used at diagnosis . µg/L

Serum IGF-1 at diagnosis

Date sample taken e.g. 31-JAN-2017 <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/> - <input type="text"/> <input type="text"/> <input type="text"/> <input type="text"/>	Serum IGF-1 assay used <i>Please tick one</i> <input type="radio"/> IDS iSYS <input type="radio"/> Immulite 2000 Family <input type="radio"/> Roche Elecsys <input type="radio"/> Siemens Immulite <input type="radio"/> Diasorin Liaison ® XL <input type="radio"/> Other	If Other, please specify <input type="text"/> <input type="text"/> <input type="text"/>
--	---	--

Serum IGF-1 concentration _____ . ____	Serum IGF-1 unit <i>Please tick one</i> <input type="radio"/> nmol/L <input type="radio"/> µg/L <input type="radio"/> ng/ml <input type="radio"/> Other
If other Serum IGF-1 unit, please specify _____	

Date of I-GHD diagnosis

Date: *e.g. 31-JAN-2017* - -

Section 5 - Routine Re-test Results

GH stimulation re-test

Date sample taken <i>e.g. 31-JAN-2017</i> <u> </u> <u> </u> - <u> </u> <u> </u> <u> </u> <u> </u> - <u> </u> <u> </u> <u> </u> <u> </u> <u> </u> <u> </u> <u> </u> <u> </u>	Peak GH _____ . ____ µg/L
--	---------------------------

Test used *Please tick one* Insulin tolerance test Arginine Glucagon Other

If 'Other' test has been used, please specify _____

Was the test sex steroid primed? *Please tick one* Yes No

Please note: for the purposes of the GHD Reversal Trial, insulin tolerance test, glucagon and arginine are stipulated as the required GH stimulation tests within the protocol.

Serum IGF-1 at re-test

Date sample taken *e.g. 31-JAN-2017* - -

Serum IGF-1 assay used <i>Please tick one</i>	If Other, please specify
<input type="radio"/> IDS iSYS <input type="radio"/> Roche Elecsys <input type="radio"/> Diasorin Liaison ® XL	_____
<input type="radio"/> Immulite 2000 Family <input type="radio"/> Siemens Immulite <input type="radio"/> Other	_____

Serum IGF-1 concentration _____ . ____

Serum IGF-1 unit *Please tick one* nmol/L µg/L ng/ml Other

If other Serum IGF-1 unit, please specify _____

Section 6 - Growth Hormone Therapy

Date GH therapy first commenced *e.g. JAN-2017*

Details of GH therapy prior to re-test

Please provide details of the participant's last GH therapy preparation and dose immediately prior to re-test in the table below.

GH Therapy Immediately Prior to Re-test

GH preparation (use Table 1)	Dose	Start date	Date of last dose prior to re-test
_____	_____ µg/kg/day	<u> </u> <u> </u> - <u> </u> <u> </u> <u> </u> <u> </u> - <u> </u> <u> </u> <u> </u> <u> </u> <u> </u> <u> </u> <u> </u> <u> </u>	<u> </u> <u> </u> - <u> </u> <u> </u> <u> </u> <u> </u> - <u> </u> <u> </u> <u> </u> <u> </u> <u> </u> <u> </u> <u> </u> <u> </u>

Has the participant been prescribed GH therapy since randomisation? *Please tick one* Yes No

Please record any GH therapy prescribed from randomisation onwards on the GHD Reversal Trial Medication Form

Section 7 - Concomitant Medication

Is the participant taking any other endocrine medication (including both new prescriptions since randomisation, and ongoing medicines at the time of randomisation)? *Please tick one* Yes No

Please record details of endocrine medication on the GHD Reversal Trial Medication Form

Section 8 - Bone-related Data

It is recommended that the X-ray is performed on the participant's non-dominant hand where possible, and the same hand should be X-rayed throughout the trial. Bone Xpert X-ray analysis is conducted at Great Ormond Street Hospital (UK participants) and Kepler Universitätsklinikum (Austrian participants). Results are sent to the participant's site and should be entered onto the trial database by site staff. Please see section 10.4 of the protocol for further details of the hand X-ray process.

Has a hand X-ray been performed? <i>Please tick one</i>		<input type="radio"/> Yes	<input type="radio"/> No
Specify hand used for X-ray <i>Please tick one</i>	<input type="radio"/> Dominant	<input type="radio"/> Non-dominant	Date of X-ray <i>e.g. 31-JAN-2017</i> <u> </u> <u> </u> <u> </u> - <u> </u> <u> </u> <u> </u> <u> </u> - <u> </u> <u> </u> <u> </u> <u> </u> <u> </u> <u> </u> <u> </u>
Bone age <u> </u> . <u> </u> years	Bone Health Index <u> </u> . <u> </u>		

Section 9 - Biochemistry

Lipid Profile

	Date sample taken	Not done	Reading	Unit	Within normal reference range?
Fasting serum triglyceride	<u> </u> <u> </u> - <u> </u> <u> </u> <u> </u> <u> </u> - <u> </u> <u> </u> <u> </u> <u> </u> <u> </u> <u> </u> <u> </u> <u> </u>	<input type="checkbox"/>	<u> </u> <u> </u> <u> </u> . <u> </u>	<input type="radio"/> mmol/L <input type="radio"/> mg/dL	<input type="radio"/> Yes <input type="radio"/> No
Fasting total serum cholesterol	<u> </u> <u> </u> - <u> </u> <u> </u> <u> </u> <u> </u> - <u> </u> <u> </u> <u> </u> <u> </u> <u> </u> <u> </u> <u> </u> <u> </u> <u> </u>	<input type="checkbox"/>	<u> </u> <u> </u> <u> </u> . <u> </u>	<input type="radio"/> mmol/L <input type="radio"/> mg/dL	<input type="radio"/> Yes <input type="radio"/> No

Section 10 - Withdrawal

Is the participant/ parent willing to continue in the trial? *Please tick one*

Yes No

If the participant is NOT willing to continue in the trial, please complete the Trial Exit/ Change of Status Form.

Section 11 - Details of worksheet completion

Completed by (name) *This person must be listed on the delegation log*

PI (or delegate) signature:

Date form completed *e.g. 31-JAN-2017* - -

Thank you for completing the GHD Reversal Trial Baseline Data Collection Worksheet. Please enter all data onto the participant's electronic case report form:

<https://www.trials.bham.ac.uk/GHD>

In addition to the baseline data collection form, please ensure the following are also completed at the time of baseline assessment:

-Child Health Utility-9D questionnaire (to be completed by the participant)

-GHD Reversal Trial Medication Form

Table 1: GH Preparation List

1.	Genotropin
2.	Humatrope
3.	Norditropin
4.	NutropinAQ
5.	Omnitrope
6.	Saizen
7.	Zomacton
8.	Other, please specify